{
    "title": "115_s778",
    "content": "The \"Prescription Drug Monitoring Act of 2017\" may be cited as the short title for this legislation. It includes definitions for various terms used in the Act. In this Act, \"controlled substance\" is defined as per the Controlled Substances Act. A \"covered State\" is one that receives funding under specific programs. A \"dispenser\" is a person authorized to deliver prescription drugs to a patient. The curr_chunk defines terms related to prescription drug monitoring programs, practitioners, and states. The curr_chunk focuses on the requirements for prescription drug monitoring programs. Beginning 2 years after enactment, covered States must require prescribing practitioners to consult the PDMP before initiating treatment with certain controlled substances and every 3 months thereafter. The PDMP must provide proactive notification of misuse patterns, and dispensers must report each instance within the State. The covered State must require dispensers to report each prescription for a controlled substance to the PDMP within 24 hours. The PDMP must provide de-identified data sets and annual reports for public and private use. Noncompliance may result in withholding grant funds. The Attorney General, in coordination with the Secretary of Health and Human Services, will award a grant to establish an inter-State data-sharing single hub to assist States in complying with prescription drug monitoring program requirements. The Attorney General and the Secretary of Health and Human Services will award a grant to establish an inter-State data-sharing single hub for sharing PDMP data among States and accessing it by practitioners. The hub will allow States to retain ownership of data, provide de-identified data for research, allow State users to access data without fees, and comply with PMIX standards. The PDMP State authority must give written consent for distributing PDMP data and cannot restrict its distribution as approved by the authority."
}